Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other financing activities (2016 - 2018)

Historic Other financing activities for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Q2 2018 value amounting to -$5.5 million.

  • Enanta Pharmaceuticals' Other financing activities changed N/A to -$5.5 million in Q2 2018 from the same period last year, while for Sep 2024 it was -$5.5 million, marking a year-over-year decrease of 6806.11%. This contributed to the annual value of $325000.0 for FY2023, which is N/A changed from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Other financing activities of -$5.5 million as of Q2 2018.
  • Enanta Pharmaceuticals' Other financing activities' 5-year high stood at $2.2 million during Q1 2018, with a 5-year trough of -$5.5 million in Q2 2018.
  • In the last 5 years, Enanta Pharmaceuticals' Other financing activities had a median value of -$2000.0 in 2016 and averaged -$222.22.
  • In the last 5 years, Enanta Pharmaceuticals' Other financing activities crashed by 16000.0% in 2015 and then surged by 176764.71% in 2016.
  • Enanta Pharmaceuticals' Other financing activities (Quarter) stood at $1.9 million in 2014, then plummeted by 100.16% to -$3000.0 in 2015, then surged by 33.33% to -$2000.0 in 2016, then tumbled by 12150.0% to -$245000.0 in 2017, then plummeted by 2146.53% to -$5.5 million in 2018.
  • Its last three reported values are -$5.5 million in Q2 2018, $2.2 million for Q1 2018, and -$245000.0 during Q4 2017.